JAMA Network
About The Study: In this phase 3 study, mRNA-1083, an investigational, multicomponent vaccine against seasonal influenza and SARS-CoV-2, met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64), the 3 clinically relevant influenza strains (among those age 65 and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
